Browsing Tag
Biogen
18 posts
Sage Therapeutics, Biogen get ZURZUVAE FDA approval for postpartum depression treatment
Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) announced the U.S. Food and Drug Administration (FDA)…
Biogen to expand portfolio with $7.3bn acquisition of Reata Pharmaceuticals
Biogen Inc. (Nasdaq: BIIB) is set to acquire Reata Pharmaceuticals, Inc. (Nasdaq: RETA) for $172.5 per share in…
Eisai, Biogen secure Leqembi FDA accelerated approval for Alzheimer’s disease
Eisai and Biogen have secured the approval of the US Food and Drug Administration (FDA) for their jointly…
Sage Therapeutics strikes $3.1bn licensing deal with biogen for depression and neurological disorder treatments
Sage Therapeutics has entered into a high-stakes global collaboration and licensing agreement with Biogen, valued at up to…
FDA accepts SB11 BLA for review: A step towards affordable treatment for retinal vascular disorders
The United States Food and Drug Administration (FDA) has recently accepted the biologics license application (BLA) for SB11,…
Mylan gets favorable court decision in Biogen’s Tecfidera patent case
Dutch generic drugmaker Mylan said that the US District Court for the Northern District of West Virginia has…
Biogen to acquire Nightstar Therapeutics in a deal worth $800m to target retinal diseases
In a significant move within the biotech sector, Biogen, the US-based biotechnology giant, has announced its agreement to…
Biogen strikes $600m deal with Pfizer for promising schizophrenia drug
Biogen, a leading US biotechnology firm, has reached a significant agreement to acquire Pfizer’s neurology drug candidate, PF-04958242,…